Previous Close | 4.5900 |
Open | 4.5700 |
Bid | 4.1100 x 1200 |
Ask | 4.7000 x 1000 |
Day's Range | 4.5000 - 4.6800 |
52 Week Range | 3.0300 - 10.3000 |
Volume | |
Avg. Volume | 94,593 |
Market Cap | 157.559M |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ACHV
SEATTLE and VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth quarter and year-end 2023 financial results and provide an update on the cytisinicline development program on Thursday, March 28, 2024, at 4:30 PM EST. To access the webcast, pleas
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Small-Cap Research. REGISTER NOW AT: https://bit.ly/3T80zZl The company presentations will be available 24/7 for 90
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences. John Bencich, CEO of Achieve, will be presenting and participating in a live panel at the Life Sciences Investor